Your browser doesn't support javascript.
loading
Effect of Radiofrequency Neurolysis on the Symptoms of Chronic Rhinitis: A Randomized Controlled Trial.
Stolovitzky, J Pablo; Ow, Randall A; Silvers, Stacey L; Bikhazi, Nadim B; Johnson, Curtis D; Takashima, Masayoshi.
Afiliação
  • Stolovitzky JP; Department of Otolaryngology, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Ow RA; Sacramento Ear Nose and Throat Medical and Surgical Group, Roseville, California, USA.
  • Silvers SL; Madison ENT & Facial Plastic Surgery, New York, New York, USA.
  • Bikhazi NB; The Ogden Clinic, Ogden, Utah, USA.
  • Johnson CD; ENT and Allergy Associates of Florida, Plantation, Florida, USA.
  • Takashima M; Department of Otolaryngology-Head & Neck Surgery, Houston Methodist Hospital, Houston, Texas, USA.
OTO Open ; 5(3): 2473974X211041124, 2021.
Article em En | MEDLINE | ID: mdl-34527852
ABSTRACT

OBJECTIVE:

To determine the safety and efficacy of temperature-controlled radiofrequency (RF) neurolysis of the posterior nasal nerve (PNN) area for the treatment of chronic rhinitis. STUDY

DESIGN:

A multicenter, prospective, single-blinded, randomized controlled trial, in which the control arm underwent a sham procedure.

SETTING:

Sixteen otolaryngology centers.

METHODS:

Patients with 24-hour reflective Total Nasal Symptom Score (rTNSS) ≥6, including moderate to severe rhinorrhea and mild to severe congestion, were randomized 21 to active treatment of the posterior nasal nerve area with a temperature-controlled RF device or a sham procedure, with no RF energy delivery. The stylus was applied bilaterally to nonoverlapping areas of the posterior middle meatus and posterior inferior turbinate in each nostril in the region of the PNN. The primary endpoint was responder rate at 3 months, where a response was defined as ≥30% improvement (decrease) in rTNSS from baseline.

RESULTS:

Patients had a mean baseline rTNSS of 8.3 (95% CI, 7.9-8.7) and 8.2 (95% CI, 7.6-8.8) (P = .797) in the active treatment (n = 77) and sham control (n = 39) arms, respectively. At 3 months, responder rate was significantly higher in the active treatment arm 67.5% (95% CI, 55.9%-77.8%) vs 41.0% (95% CI, 25.6%-57.9%) (P = .009). The active treatment arm had a significantly greater decrease in rTNSS (mean, -3.6 [95% CI, -4.2 to -3.0] vs -2.2 [95% CI, -3.2 to -1.3]) (P = .013). Three adverse events related to the device/procedure were reported, and all resolved.

CONCLUSION:

This randomized controlled trial showed temperature-controlled neurolysis of the PNN area is free from significant adverse events and superior to a sham procedure in decreasing the symptom burden of chronic rhinitis.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Diagnostic_studies Idioma: En Revista: OTO Open Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Diagnostic_studies Idioma: En Revista: OTO Open Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos